Mucosal administrations, such as intranasal and pulmonary, have been reported to effectively induce mucosal IgA and prevent respiratory infections (Giri et al., 2005; Ainai et al., 2017). This evidence concerns the gene CD79A and respiratory tract infectious disorder.